engineered an in situ DC vaccine, termed HELA‐Exos, by loading immunogenic cell death immunogenic cell death (ICD) inducers, human neutrophil elastase (ELANE) and Hiltonol (TLR3 agonist) into BC‐derived exosomes engineered with α‐lactalbumin (α‐LA). This evidence concerns the gene ELANE and breast cancer.